UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Clinical cancer research, 2018-06, Vol.24 (11), p.2631-2641

2018

Link zum Volltext

Verfügbarkeit prüfen

Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates

Pharmaceutical research, 2021-03, Vol.38 (3), p.415-428

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells

The AAPS journal, 2019-12, Vol.22 (1), p.16, Article 16

2019

Link zum Volltext

Verfügbarkeit prüfen

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Investigational new drugs, 2020-12, Vol.38 (6), p.1796-1806

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

CPT: pharmacometrics and systems pharmacology, 2021-11, Vol.10 (11), p.1396-1411

2021

Link zum Volltext

Verfügbarkeit prüfen

A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat

Pharmaceutical research, 2013-06, Vol.30 (6), p.1536-1552

2013

Link zum Volltext

Verfügbarkeit prüfen

Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers

Clinical and translational science, 2024-03, Vol.17 (3), p.e13756-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

Pharmaceutical research, 2013-10, Vol.30 (10), p.2640-2653

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study

Clinical pharmacology and therapeutics, 2021-06, Vol.109 (6), p.1618-1630

2021

Link zum Volltext

Verfügbarkeit prüfen

Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

European journal of pharmaceutical sciences, 2021-10, Vol.165, p.105932-105932, Article 105932

2021

Link zum Volltext

Verfügbarkeit prüfen

Development of a physiologically-based pharmacokinetic model of the rat central nervous system

Pharmaceutics, 2014-03, Vol.6 (1), p.97-136

2014

Link zum Volltext

Verfügbarkeit prüfen

Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials

Drug discovery today, 2023-07, Vol.28 (7), p.103605-103605, Article 103605

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Journal of pharmacokinetics and pharmacodynamics, 2009-08, Vol.36 (4), p.317-339

2009

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method

The AAPS journal, 2020-10, Vol.22 (6), Article 129

2020

Link zum Volltext

Verfügbarkeit prüfen

Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

The AAPS journal, 2020-01, Vol.22 (1), p.4, Article 4

2020

Link zum Volltext

Verfügbarkeit prüfen

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example

Clinical pharmacology and therapeutics, 2023-02, Vol.113 (2), p.310-320

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Modeling of Free Amoxicillin Concentrations in Rat Muscle Extracellular Fluids Determined by Microdialysis

Antimicrobial Agents and Chemotherapy, 2005-09, Vol.49 (9), p.3702-3706

2005

Link zum Volltext

Verfügbarkeit prüfen

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling

European journal of pharmaceutical sciences, 2017-08, Vol.106, p.122-132

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of interleukin‐6 on drug transporters and permeability in the hCMEC/D3 blood–brain barrier model

Fundamental & clinical pharmacology, 2021-04, Vol.35 (2), p.397-409

2021

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Clinical pharmacology and therapeutics, 2021-03, Vol.109 (3), p.605-618

2021

Link zum Volltext

Verfügbarkeit prüfen

Norfloxacin Blood-Brain Barrier Transport in Rats Is Not Affected by Probenecid Coadministration

Antimicrobial Agents and Chemotherapy, 2006-01, Vol.50 (1), p.371-373

2006

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy

Drug metabolism and disposition, 2019-06, Vol.47 (6), p.648-656

2019

Link zum Volltext

Verfügbarkeit prüfen

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Clinical pharmacology and therapeutics, 2018-03, Vol.103 (3), p.378-383

2018

Link zum Volltext

Verfügbarkeit prüfen

Transforming Translation Through Quantitative Pharmacology for High‐Impact Decision Making in Drug Discovery and Development

Clinical pharmacology and therapeutics, 2020-06, Vol.107 (6), p.1285-1289

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates

The AAPS journal, 2015-05, Vol.17 (3), p.597-608

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBiometrics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(47)
Pharmacology & Pharmacy
(42)
Humans
(27)
Pharmacology/toxicology
(21)
Biochemistry
(17)
Biomedical And Life Sciences
(17)
Biomedicine
(17)
Models, Biological
(17)
Pharmacy
(17)
Pharmacology
(16)
Computer Simulation
(15)
Pharmacokinetics
(15)
Male
(14)
Animals
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Pharmacology. Drug Treatments
(12)
Biotechnology
(11)
Biomedical Engineering And Bioengineering
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates

Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat

Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers

Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study

Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

Development of a physiologically-based pharmacokinetic model of the rat central nervous system

Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method

Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example

Pharmacokinetic Modeling of Free Amoxicillin Concentrations in Rat Muscle Extracellular Fluids Determined by Microdialysis

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling

Impact of interleukin‐6 on drug transporters and permeability in the hCMEC/D3 blood–brain barrier model

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Norfloxacin Blood-Brain Barrier Transport in Rats Is Not Affected by Probenecid Coadministration

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Transforming Translation Through Quantitative Pharmacology for High‐Impact Decision Making in Drug Discovery and Development

Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates

Aktive Filter

Suchergebnisse filtern